The PurpleLab®
Life Sciences
Articles
PurpleLab was selected to present a poster at PMSA 2024 on imputing SDOH information on pharmacy claims. This study was centered around prescription fill rates of Semaglutides in the adolescent population. In December of 2022, the FDA approved adolescents BMI at or above the 95th percentile eligible for a Semaglutide prescription. PurpleLab used a combination…
Articles
A large CRO has incorporated PurpleLab data directly into their workflow to support all therapeutic areas and phases of clinical trial work from RWE and pre-award through phase IV and beyond including market access and HEOR work. This strategy has been incorporated for all of their clients. “The data and services provided by PurpleLab have…
Whitepapers
Cookie-less Marketing for Pharmaceuticals and the Role of Real-World Data (RWD) Life Sciences Pharmaceutical marketing is undergoing a significant transformation as third-party cookies become obsolete. To navigate this shift, pharmaceutical companies must embrace cookie-less marketing strategies, leveraging real-world data throughout the advertising campaign lifecycle. In this whitepaper, we explore: The impact of cookie-less marketing on…
Whitepapers
Impact of Applying SDOH on Prescription Fill Rate Analysis Life Sciences This whitepaper highlights the significance of understanding prescription rejection rates, particularly for specialty pharmacy medications, and the role of plan design and social determinants of health (SDOH) in determining eligibility and out-of-pocket costs for patients. Traditional analyses focusing solely on demographics like age and…
Whitepapers
New Treatments Hold Significant Promise, but are Marketing Teams Helping Life Sciences Companies Deliver on this Potential? Life Sciences Download
Webinars
Join the PurpleLab team in this on-demand webinar discussing how Real-World Data can address the FDA mandate to develop a Race and Ethnicity Diversity Plan in clinical trials. Shannon LaRusso, SVP of Product Management, and Russell Robbins, MD, CMIO discuss:
Solution Sheets
CLEAR Claims Life Sciences Life Sciences Download
Articles
Osteoporosis and low bone mass affect almost 54 million people in the US, placing them at risk for hip, spine, wrist fractures, permanent pain, limited mobility, and increased morbidity and mortality. The disease affects people of all races, ethnicities, and gender, although significant variation within these groups does exist. For the over fifty population, osteoporosis…